Patent SG-11201805872S-A (SG)
Title: Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
Inventor: WONG OI KWAN
IPC: C07K16/30
Filed: 2017-01-10
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111011110111111111101111101111011111 International Bureau ... ..51 jd (10) International Publication Number ..... ..... ..r .,,,i (43) International Publication Date WO 2017/125830 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07K 14/47 (2006.01) C07K 16/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, A61K 38/00 (2006.01) C07K 16/30 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, A61K 48/00 (2006.01) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (21) International Application Number: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, PCT/IB2017/050108 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: ZA, ZM, ZW. 10 January 2017 (10.01.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/281,533 21 January 2016 (21.01.2016) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/431,758 8 December 2016 (08.12.2016) US LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GW, KM, ML, MR, NE, SN, TD, TG). New York, NY 10017 (US). Declarations under Rule 4.17: (72) Inventors: WONG, Oi Kwan; 15 Arroyo View Circle, — as to the identity of the inventor (Rule 4.17(i)) Belmont, CA 94002 (US). CHOU, Joyce Ching; 767 — Silkoak Way, Sunnyvale, CA 94086 (US). DUSSEAUX, — as to applicant's entitlement to apply for and be granted a — Mathilde Brunnhilde; 19 domaine de Chateau, _ Gaillard, patent (Rule 4.17(ii)) 1675 as to the applicant's entitlement to claim the priority of the = 94700 Maisons-Alfort (FR). SMITH, Julianne; application (Rule 4.17(iii)) York Avenue, New York (US). , NY 10128 —earlier East 42nd Published: (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 Street, MS 235/9/S20, New York, NY 10017 = (US). — with international search report (Art. 21(3)) for every (81) Designated States (unless otherwise indicated, kind AE, AG, AL, AM, with sequence listing part of description (Rule 5.2(a)) of national protection available): AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, DJ, DK, DM, = BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, = = = = = TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III (54) Title: CHIMERIC ANTIGEN RECEPTORS = 'IA HG. loo 80 - N. M F98 (EGFR Negative) 1-1 60 40 en 20 GO ir) 0 I -7) „..,. n F98 -EGFRwt Ei F98 -EGFRvill ell 0 10 2 10 3 10 4 10 5 - IN 1-1 (57) : The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRv111 (Epidermal Growth N Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nude - ic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic C methods for using these CARs and engineered immune cells for the treatment of EGFRv111-mediated pathologies, including cancers such as glioblastoma.